Ketamine therapy is legal in the United States, but the rules depend on the type of ketamine, how it’s administered, and what it’s being used for. The landscape can feel confusing because ketamine occupies an unusual legal space: it’s a Schedule III controlled substance with FDA approval only as an anesthetic, yet hundreds of clinics across the country legally offer it off-label for depression, anxiety, PTSD, and chronic pain.
How Ketamine Is Classified Under Federal Law
Ketamine became a Schedule III non-narcotic controlled substance in 1999 under the Controlled Substances Act. That classification means it has accepted medical uses but also carries potential for abuse, which may lead to moderate physical dependence or high psychological dependence. Schedule III is the same tier as testosterone and certain codeine combinations, so it requires a prescription but faces fewer restrictions than Schedule II drugs like oxycodone or amphetamines.
Being Schedule III means ketamine can only be legally obtained through a licensed prescriber for a legitimate medical purpose. Possessing, selling, or manufacturing it outside that medical context is a federal crime. The recreational version, sometimes called Special K, has been illicitly manufactured and sold at clubs and festivals for decades, and carries the same criminal penalties as any other illegal drug possession.
What the FDA Has Actually Approved
The FDA has approved ketamine for one specific use: induction and maintenance of general anesthesia, administered by injection. That approval dates back decades and covers the generic injectable form (branded as Ketalar).
In 2019, the FDA approved a separate but related drug called esketamine, sold as Spravato. This nasal spray contains only one of the two mirror-image molecules found in regular ketamine. Spravato is approved for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It must be used alongside an oral antidepressant.
Ketamine itself is not FDA-approved for the treatment of any psychiatric disorder, including depression, anxiety, or PTSD. This is an important distinction that shapes how the drug is legally prescribed and administered for mental health conditions.
Why Off-Label Prescribing Is Legal
If ketamine isn’t approved for depression, how can clinics legally offer it for that purpose? The answer lies in a well-established medical practice called off-label prescribing. The FDA regulates drug approval but has traditionally not regulated how physicians practice medicine. Once a drug is approved for any indication, licensed physicians can prescribe it for other conditions if they believe the benefits outweigh the risks for a particular patient.
Off-label prescribing is extremely common across all areas of medicine. It’s how many cancer drugs, pediatric medications, and psychiatric treatments are used. When a clinic offers ketamine infusions for depression or chronic pain, it’s operating within this legal framework. The prescribing physician takes on the responsibility of justifying the medical decision, but no law prevents them from making it.
Spravato Has Stricter Rules Than Generic Ketamine
Spravato comes with a mandatory safety program called REMS (Risk Evaluation and Mitigation Strategy) that imposes specific legal requirements on how it’s dispensed. Healthcare settings must be certified in the program. Patients must be enrolled. The drug can only be administered under direct observation of a healthcare provider, never taken home. After each dose, patients must be monitored for at least two hours, with blood pressure checks before and after treatment. A prescriber must be onsite during the entire administration and monitoring period. Patients need a caregiver or family member to drive them home afterward and are told not to drive or operate machinery until the next day after a full night’s sleep.
These restrictions exist because esketamine causes sedation and dissociation, and the FDA wanted safeguards against misuse built into the distribution system. Clinics that fail to follow the REMS requirements risk losing their certification and face potential legal consequences.
What’s Required to Run a Ketamine Clinic
For generic (off-label) ketamine, there is no federal REMS program, and requirements vary by state. However, major psychiatric and pain management societies recommend that ketamine infusions be performed only under the care of a physician with Advanced Cardiac Life Support (ACLS) certification. When higher doses are used, particularly for chronic pain, supervising physicians should also meet anesthesiology standards for moderate sedation.
Some state medical boards have issued specific guidelines. Alabama, for example, requires that only a licensed physician may prescribe ketamine for treatment-resistant depression. That physician must be ACLS certified, trained in ketamine use, and present onsite during administration. If the prescribing doctor is not a psychiatrist, a psychiatrist or primary care physician must confirm the diagnosis first. Any nurses or other staff assisting with administration must also hold ACLS certification. Alabama’s guidelines explicitly state that a physician should never allow a patient to self-administer ketamine at home for psychiatric reasons.
Not every state has issued such detailed rules, which is part of why the ketamine clinic landscape varies so widely in quality and oversight. Some states have minimal specific regulation beyond standard medical practice laws, while others have adopted or are developing more prescriptive frameworks.
At-Home Ketamine Lozenges and Compounded Products
Some companies, particularly telehealth platforms, prescribe compounded ketamine products like lozenges or nasal sprays for patients to use at home. These products exist in a legal gray area that has drawn FDA scrutiny. Compounded ketamine products are not FDA-approved for any indication, have not been evaluated for safety or effectiveness, and are not part of any REMS monitoring program.
The FDA issued a warning specifically about these products, noting that at-home administration creates additional risks because no healthcare provider is onsite to monitor for serious adverse outcomes from sedation and dissociation. The agency acknowledged that the convenience of obtaining ketamine through telehealth for home use is attractive to patients, but emphasized that the lack of monitoring puts them at risk.
Prescribing compounded ketamine for home use is not explicitly illegal under federal law. Compounding pharmacies operate under their own set of FDA regulations, and physicians retain the ability to prescribe compounded medications. But the practice conflicts with the recommendations of most medical boards and professional societies, and some states may restrict or prohibit it.
Telehealth Prescribing Rules
Federal law normally requires an in-person medical evaluation before a provider can prescribe a controlled substance. This rule, established by the Ryan Haight Act, would technically require ketamine patients to see a prescriber face-to-face before receiving a prescription. During the COVID-19 pandemic, this requirement was temporarily suspended, and the flexibility has been extended multiple times since.
As of the most recent extension, patients can continue receiving controlled substance prescriptions via telehealth without a prior in-person visit through the end of 2026. The DEA and HHS are working on permanent regulations, including a proposed special registration for telemedicine prescribing. Until those rules are finalized, telehealth ketamine services operate under the temporary flexibilities, though all prescriptions must still be issued for legitimate medical purposes by licensed practitioners in compliance with federal and state law.
Legal Status Outside the United States
In Canada, ketamine is controlled under Schedule I of the Controlled Drugs and Substances Act, a more restrictive classification than in the U.S. Activities like sale, possession, or production are illegal unless authorized for medical, scientific, or industrial purposes. Ketamine does have legitimate medical uses in Canada, but access for psychiatric treatment is more tightly controlled than in American clinics.
The legal status varies significantly across other countries. In most places, ketamine is a controlled substance available for medical use but restricted or prohibited recreationally. The specific rules around off-label psychiatric use, telehealth prescribing, and at-home administration differ from country to country.
The Line Between Legal and Illegal Use
The distinction is straightforward in principle: ketamine obtained through a licensed prescriber for a documented medical purpose is legal. Ketamine obtained outside the medical system, whether purchased on the street, online without a prescription, or diverted from a medical supply, is illegal. Possession without a valid prescription carries criminal penalties that vary by state but can include jail time, particularly for larger quantities or evidence of intent to distribute.
For patients considering ketamine therapy, the legal risk is minimal as long as you’re working with a licensed provider and using the medication as prescribed. The more relevant concern is quality of care. Because off-label ketamine clinics operate with relatively little standardized oversight compared to Spravato’s strict REMS program, the level of monitoring, medical expertise, and safety protocols can vary dramatically from one clinic to the next.